Which medications in the drug class Monoclonal Antibodies are used in the treatment of B-Cell Lymphoma?

Updated: Feb 23, 2021
  • Author: Mohammad Muhsin Chisti, MD, FACP; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Monoclonal Antibodies

The agents in this class target specific antigens in carcinoma cells and induce cytotoxicity.

Ibritumomab tiuxetan (Zevalin Y-90)

A murine monoclonal antibody that targets the CD20 antigen, ibritumomab tiuxetan is chelated to the radioisotopes indium-111 or yttrium-90. It is used in conjunction with rituximab to treat B-cell NHL or rituximab-refractory follicular NHL. The regimen consists of two low doses of rituximab, an imaging dose, two-three whole-body scans, and a therapeutic dose, all of which are delivered in an outpatient setting over 8 days.

Ofatumumab (Arzerra)

Ofatumumab is an anti-CD20 human monoclonal antibody that inhibits B-cell activation in early stages. It is indicated for chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.

Alemtuzumab (Lemtrada, Campath)

Alemtuzumab is a monoclonal antibody against CD52, an antigen found on B cells, T cells, and almost all chronic lymphocytic leukemia cells. It binds to the CD52 receptor of the lymphocytes, which slows the proliferation of leukocytes.

Rituximab (Rituxan)

Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an immunoglobulin G1 (IgG1) kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences.

Polatuzumab vedotin (Polatuzumab vedotin-piiq, Polivy)

Polatuzumab is a CD79b-directed antibody-drug conjugate with activity against dividing B cells. MMAE is an antimitotic agent covalently attached to the antibody via a cleavable linker. The monoclonal antibody binds to CD79b, where polatuzumab is internalized and linker is cleaved by lysosomal proteases to enable intracellular delivery of MMAE. MMAE binds to microtubules and kills dividing cells by inhibiting cell division and inducing apoptosis. It is indicated, in combination with bendamustine and a rituximab product is indicated for relapsed or refractory DLBCL, not otherwise specified, after at least 2 prior therapies.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!